David R. Guyer

Advisor at Re-Vana Therapeutics

Co-Founder, ex-CEO and Executive Chairman of the Board of Ophthotech Corporation, Dr. Guyer has significant medical, drug development and commercial experience in ophthalmology. Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings over $400 million, including a $157 million IPO offering. He also oversaw the rapid development and successful commercialization of Macugen® (pegaptanib sodium), the first FDA-approved anti-VEGF pharmacological treatment for wet AMD. Dr. Guyer previously worked as a venture capitalist and Partner at SV Life Sciences and has served on multiple Boards of both public and private companies.

Roles

  • Advisor

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.